Medical Equipment & Devices

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

While some brokers maintain valuation concerns, the Nanosonics share price rallied strongly on bullish revenue guidance and prospects for the launch of a new product in 2023

Aug 26 2021

Noting Pro Medicus follows a consistent rally-consolidate-rally pattern, Michael Gable of Fairmont Equities suggests another consolidation would offer a good entry point

Aug 24 2021


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
CAT CATAPULT GROUP INTERNATIONAL LIMITED $1.99 $2.33 $1.61

$2.45

CBL CONTROL BIONICS LIMITED $0.68 $1.03 $0.52

$1.42

COH COCHLEAR LIMITED $234.72 $257.76 $176.68 56.5

$228.917

FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED $30.33 $34.77 $25.25 49.6

$32.50

IDX INTEGRAL DIAGNOSTICS LIMITED $4.71 $5.55 $3.96 24.6

$5.08

IME IMEXHS LIMITED $1.43 $xx.xx $xx.xx xx.x xx.xx
IPD IMPEDIMED LIMITED $0.11 $xx.xx $xx.xx xx.x xx.xx
MX1 MICRO-X LIMITED $0.30 $xx.xx $xx.xx xx.x xx.xx
NAN NANOSONICS LIMITED $6.40 $xx.xx $xx.xx xx.x xx.xx
PME PRO MEDICUS LIMITED $59.32 $xx.xx $xx.xx xx.x xx.xx
RMD RESMED INC $39.80 $xx.xx $xx.xx xx.x xx.xx
SOM SOMNOMED LIMITED $2.31 $xx.xx $xx.xx xx.x xx.xx
VHT VOLPARA HEALTH TECHNOLOGIES LIMITED $1.23 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Breakout For Cochlear

Aug 10 2021

Michael Gable of Fairmont Equities notes that having suffered a sharp sell-off in July, Cochlear has now broken up through resistance


Will ResMed’s Market Share Gains Last?

Aug 09 2021

Notwithstanding the difficulties in satisfying a surge in demand for sleep apnoea devices, ResMed should win market share. The main question is how much?


Treasure Chest: Has Nanosonics Been Too Successful?

Jul 08 2021

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. While some views on Nanosonics remain positive, recent research highlights the company may become a victim of prior success


Opportunity For ResMed Following Philips Recall

Jun 16 2021

ResMed has reported increased engagement with potential CPAP customers as a result of the Philips recall, although the opportunity could be limited by supply constraints


Treasure Chest: How Much Covid Impact For Nanosonics?

May 13 2021

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Amidst divergent views on Nanosonics, Bell Potter has identified the company as a primary victim of global covid¬†restrictions and delays


Who Will Be The Next Pro Medicus?

May 13 2021

The New Criterion’s Tim Boreham highlights some interesting ASX-listed stocks revolutionizing the diagnostic imaging industry


New Product, Patient Growth Key To ResMed

May 03 2021

Over the short term ResMed could find it difficult to surmount obstacles created by the pandemic while there is general agreement on an eventual return to growth


Growth For ResMed Despite Challenges

Feb 01 2021

Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge


Short-Term Risks Remain For Nanosonics

Nov 05 2020

Heightened interest in infection prevention should be of benefit to Nanosonics in the wake of the pandemic, although rising cases in the short term create risks.


Home Health The Way Forward For ResMed

Nov 02 2020

ResMed has plenty of irons in the fire, well placed to grow from increases in home health care despite the likelihood ventilator sales will decline rapidly from the peak during the pandemic.